Invivyd (IVVD) Depreciation and Depletion (2021 - 2024)
Invivyd's (IVVD) quarterly Depreciation and Depletion came in at $132000.0 in Q3 2024, up 10.92% YoY from $119000.0 in Q4 2023, and up 3.12% on a QoQ basis from $128000.0 in Q2 2024.
Invivyd (IVVD) Depreciation and Depletion (2021 - 2024) Analysis & Trends
Invivyd (IVVD) has 4 years of Depreciation and Depletion data on file, last reported at $132000.0 in Q3 2024.
- Quarterly Depreciation and Depletion rose 10.92% year-over-year to $132000.0 in Q3 2024, while the trailing twelve-month figure through Sep 2024 was $502000.0 (up 29.72% YoY) and the FY2023 annual result came in at $480000.0, up 1070.73% from the prior year.
- Depreciation and Depletion rose to $132000.0 in Q3 2024, from $128000.0 in the prior quarter.
- In the past five years, Depreciation and Depletion ranged from a high of $132000.0 in Q3 2024 to a low of $1000.0 in Q4 2021.
- A 4-year average of $75333.3 and a median of $119500.0 in 2023 frame the typical range for Depreciation and Depletion.
- Annual changes were most pronounced in 2023 — Depreciation and Depletion soared 2900.0% — and 2024, when it gained 1.67%.
- Tracing IVVD's Depreciation and Depletion over 4 years: stood at $1000.0 in 2021, then surged by 2600.0% to $27000.0 in 2022, then surged by 344.44% to $120000.0 in 2023, then climbed by 10.0% to $132000.0 in 2024.
- The last three Depreciation and Depletion figures came in at $132000.0 (Q3 2024), $128000.0 (Q2 2024), and $122000.0 (Q1 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation and Depletion (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.10 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 38.91 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 3.18 Mn |
| 10 | Invivyd | 212.23 Mn | 52.15 Mn | 13.01 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 132,000.00 |
| Sep 30, 2024 | 132,000.00 |
| Jun 30, 2024 | 128,000.00 |
| Jun 30, 2024 | 128,000.00 |
| Mar 31, 2024 | 122,000.00 |
| Mar 31, 2024 | 122,000.00 |
| Dec 31, 2023 | 120,000.00 |
| Dec 31, 2023 | 120,000.00 |
| Sep 30, 2023 | 119,000.00 |
| Sep 30, 2023 | 119,000.00 |
| Jun 30, 2023 | 121,000.00 |
| Jun 30, 2023 | 121,000.00 |
| Mar 31, 2023 | 120,000.00 |
| Mar 31, 2023 | 120,000.00 |
| Dec 31, 2022 | 27,000.00 |
| Dec 31, 2022 | 27,000.00 |
| Sep 30, 2022 | 5,000.00 |
| Sep 30, 2022 | 5,000.00 |
| Jun 30, 2022 | 5,000.00 |
| Jun 30, 2022 | 5,000.00 |